On Monday, DiaMedica Therapeutics Inc (NASDAQ: DMAC) opened higher 8.09% from the last session, before settling in for the closing price of $5.93. Price fluctuations for DMAC have ranged from $3.19 to $7.49 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 7.39% over the past five years. Company’s average yearly earnings per share was noted -14.00% at the time writing. With a float of $24.57 million, this company’s outstanding shares have now reached $52.08 million.
DiaMedica Therapeutics Inc (DMAC) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of DiaMedica Therapeutics Inc is 52.82%, while institutional ownership is 24.91%. The most recent insider transaction that took place on Aug 25 ’25, was worth 2,029,252. In this transaction 10% Owner of this company bought 338,265 shares at a rate of $6.00, taking the stock ownership to the 7,654,045 shares. Before that another transaction happened on Aug 13 ’25, when Company’s 10% Owner bought 293,601 for $5.91, making the entire transaction worth $1,734,918. This insider now owns 7,058,066 shares in total.
DiaMedica Therapeutics Inc (DMAC) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.18 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.17) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -14.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -13.62% during the next five years compared to 7.39% growth over the previous five years of trading.
DiaMedica Therapeutics Inc (NASDAQ: DMAC) Trading Performance Indicators
Check out the current performance indicators for DiaMedica Therapeutics Inc (DMAC). In the past quarter, the stock posted a quick ratio of 10.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.72, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -0.76 in one year’s time.
Technical Analysis of DiaMedica Therapeutics Inc (DMAC)
DiaMedica Therapeutics Inc (NASDAQ: DMAC) saw its 5-day average volume 0.62 million, a positive change from its year-to-date volume of 0.23 million. As of the previous 9 days, the stock’s Stochastic %D was 40.42%.
During the past 100 days, DiaMedica Therapeutics Inc’s (DMAC) raw stochastic average was set at 73.10%, which indicates a significant increase from 59.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.47 in the past 14 days, which was higher than the 0.38 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.76, while its 200-day Moving Average is $5.22. Nevertheless, the first resistance level for the watch stands at $6.83 in the near term. At $7.26, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.77. If the price goes on to break the first support level at $5.89, it is likely to go to the next support level at $5.38. Assuming the price breaks the second support level, the third support level stands at $4.95.
DiaMedica Therapeutics Inc (NASDAQ: DMAC) Key Stats
There are currently 52,077K shares outstanding in the company with a market cap of 333.82 million. Presently, the company’s annual sales total 0 K according to its annual income of -24,440 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -7,700 K.
